with:
! is the time at which the individual initiates ART i.e. when her CD4 count reaches 350 cells/mm 3 . 4 !" is the CD4 count at which the individual would be given LLIN and WF, is the discount rate (3%), !"# is the unit cost of one patient-year on ART, !"# is the mean lifetime on ART assumed to be 33 years when individuals initiate ART at a CD4 count of 350 cells/mm 3 : this figure is an average between a Ugandan estimate (36 years) [1] and a South African estimate (29 years) [2] . When 4 !" = 500 cells/mm 3 , ! = 70 cells/mm 3 /year: ! = 2.1 years, and ! = $15,480 for !"# = $757.
Consider individuals receiving LLIN and WF. Lifetime ART costs for one of these individuals is given by:
! is the time at which the individual initiates ART i.e. when her CD4 count reaches 350 cells/mm 3 . When 4 !" = 500 cells/mm 3 , ! = 70 cells/mm 3 /year: ! = 2.7 years, and ! = $15,110 for !"# = $757.
Subsequently, for N individuals whose CD4 > 350, we encounter the following ART cost savings (due to discounting):
and the following return on investment (ROI):
The ROI can further be expressed as:
2. Country-specific inputs and results Table S1 presents country-specific parameters used in our calculations. These include: Table S1 , we estimate that there are a total of about 70,000 recipients of the LLIN-WF intervention in Kenya. 
Country-specific inputs
prevalence
Sensitivity analyses

Multivariate sensitivity analysis
We conducted a Monte Carlo multivariate sensitivity analysis to estimate aggregate uncertainty from key inputs. Parameters were given values using probability distributions (details are given in Table S2 ). Table S2 . Probability distributions of the key inputs for the intervention providing bednets and water filters to HIV-positive adults to delay HIV disease progression in Kenya.
Input Parameters
Intervention cost
Gamma with mean = 32, SD = 5
Annual ART cost per patient Gamma with mean = 500, SD = 25 SD, standard deviation; ART, antiretroviral therapy; LLIN, long-lasting insecticide-treated bednet; WF, water filter.
Lifetime ART costs associated with HIV infections due to delayed ART
The total number of HIV infections that can be attributed to deferred ART corresponds to the number of years of life not on ART multiplied by the number of infections per year not on ART (0.05 [4] ). Given the fact that individuals are in HIV care
and have received HIV counseling and condoms, 0.05 is a high value which will lead to the estimation of a worst-case scenario. If the total number of individuals receiving LLIN-WF is , the total number of years of life 'not on ART' or 'shifted' (discounted at = 3%) is given by:
as derived from (1-4), which is estimated at about 56,000 for Kenya, leading to about 2,800 new infections not averted by ART.
The annual cost for a person on ART is assumed to be !"# = $757. The figure of $757 per person-year of ART is the authors' construction and is an average cost figure derived from the cost figures reported for low-income countries (Benin, Ethiopia, Haiti, Uganda) from a recent review article [5] , combined with recently published cost estimates for Ethiopia and Uganda from two PEPFAR-supported country programs [6] , and from cost estimates for rural Uganda and the average cost for 45 sites in Zambia, extracted from two additional publications [7, 8] . Further details on the authors' construction can be obtained upon request.
The expected total lifetime cost of providing ART to one individual, LC ART , is discounted to present value using an annual discount rate r = 3%. An HIV-infected individual is assumed to initiate ART with a probability of 0.70 (ART coverage for individuals with CD4 > 350 cells/mm 3 is currently 68% in sub-Saharan Africa [3] ).
Conditional on ART initiation, a ½ chance is assumed for early ART initiation (when CD4 count reaches 350 cells per mm 3 , at about 4.8 years since infection [9, 10] ) and the subsequent lifetime on ART is assumed to be 33 years. This figure is an average between a Ugandan estimate (36 years) [1] and a South African estimate (29 years) [2] . The remaining ½ chance is assumed for late ART initiation (when CD4 is below 200 cells/mm 3 , at about 9.4 years since infection [9, 10] ) and the subsequent lifetime on ART is assumed to be 11 years. This figure is derived from an analysis which synthesized data from 34 HIV treatment cohorts in sub-Saharan Africa and accounted for loss to follow-up [11] . Hence:
We estimated: LC ART = $7,060. This could translate to $11 million (discounted) lifetime ART costs and subsequent decreased ART cost savings of $14 million for the intervention. Evidently, these costs are sensitive to the assumptions retained, including the fraction of HIV-infected individuals that initiate ART and the fraction of those individuals that initiate ART late as opposed to early, and the subsequent duration of ART that is affected by drop-out rates and loss to follow-up.
